A systematic review and meta-analysis on the efficacy outcomes of selective serotonin reuptake inhibitors in depression in Alzheimer’s disease

[21] Steele C(2001)A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer’s disease Int Psychogeriatr 13 233-560

[22] Rovner B(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews Syst Rev 10 1-931

[23] Chase GA(2003)Measuring inconsistency in meta-analyses BMJ 327 557-411

[24] Folstein M(2019)Sertraline and mirtazapine versus placebo in subgroups of depression in dementia: findings from the HTA-SADD randomized controlled trial Am J Geriatr Psychiatry 27 920-108

[25] Rabins PV(2011)Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial Lancet 378 403-74

[26] Blacker D(1998)A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia Int J Geriatr Psychiatry 13 100-487

[27] Rovner BW(2000)A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease Am J Geriatr Psychiatry 8 66-498

[28] Rummans T(2007)Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial J Clin Psychopharmacol 27 484-901

[29] Schneider LS(2004)Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer’s disease study (DIADS) Am J Geriatr Psychiatry 12 491-52

[30] Tariot PN(1990)The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A nordic multicentre study Br J Psychiatry 157 894-274

[21] Steele C(2001)A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer’s disease Int Psychogeriatr 13 233-560

[22] Rovner B(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews Syst Rev 10 1-931

[23] Chase GA(2003)Measuring inconsistency in meta-analyses BMJ 327 557-411

[24] Folstein M(2019)Sertraline and mirtazapine versus placebo in subgroups of depression in dementia: findings from the HTA-SADD randomized controlled trial Am J Geriatr Psychiatry 27 920-108

[25] Rabins PV(2011)Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial Lancet 378 403-74

[26] Blacker D(1998)A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia Int J Geriatr Psychiatry 13 100-487

[27] Rovner BW(2000)A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease Am J Geriatr Psychiatry 8 66-498

[28] Rummans T(2007)Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial J Clin Psychopharmacol 27 484-901

[29] Schneider LS(2004)Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer’s disease study (DIADS) Am J Geriatr Psychiatry 12 491-52

[30] Tariot PN(1990)The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A nordic multicentre study Br J Psychiatry 157 894-274